Pavel Klener
YOU?
Author Swipe
View article: Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma
Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma Open
Introduction. Polatuzumab Vedotin (PV) is an antibody-drug conjugate of anti-CD79B monoclonal antibody linked with monomethyl auristatin E (MMAE), a microtubule inhibitor. PV was FDA approved in the first line treatment of large B-cell lym…
View article: FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis Open
Introduction Marginal zone lymphoma (MZL) is an indolent and heterogenous disease. Several prognostic models have been proposed to assess outcomes in MZL, including FLIPI, IPI (primarily designed for overall survival [OS]), and MZL-specifi…
Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy Open
High-dose therapy with cytarabine (araC) is a standard treatment for aggressive non-Hodgkin lymphomas, but its efficacy is limited by rapid enzymatic degradation. To overcome this, araC was conjugated to N-(2-hydroxypropyl)methacrylamide (…
View article: EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a relatively rare B‐cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely…
View article: Circulating tumour <scp>DNA</scp> as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice
Circulating tumour <span>DNA</span> as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice Open
Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B-cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real-world studies were limited. Using a targeted sequencing approach (521-gene pa…
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas Open
The current frontline therapy for B-cell non-Hodgkin lymphomas (B-NHL), the most frequent hematologic malignancy in the Western hemisphere, is based on immunochemotherapy (ICT), i.e., a combination of genotoxic cytostatics and the anti-CD2…
View article: Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy Open
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphomas (NHL), representing 3-10% of all NHL cases. The hallmark of MCL is translocation t(11;14)(q13;q32), leading to the overexpression of a crucial regulator of cell c…
View article: <i>Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?</i>
<i>Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?</i> Open
Background: Therapy of younger patients (pts) with mantle cell lymphoma (MCL) has been established as the alternation of R(ituximab)-CHOP, and high-dose cytarabine (HDA) +/- platinum-based regimen, consolidation with autologous stem cell t…
View article: Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice
Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice Open
Introduction: Circulating tumor DNA (ctDNA) could be used as a sensitive biomarker of treatment response and outcomes in patients (pts) with lymphomas including diffuse large B-cell lymphoma (DLBCL). However, there is still limited data on…
Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events Open
This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy s…
View article: Impact of <i>PIK3CA</i> gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies
Impact of <i>PIK3CA</i> gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies Open
Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN …
View article: Second bone marrow transplantation into regenerating hematopoiesis enhances reconstitution of immune system
Second bone marrow transplantation into regenerating hematopoiesis enhances reconstitution of immune system Open
In bone marrow transplantation (BMT), hematopoiesis-reconstituting cells are introduced following myeloablative treatment, which eradicates existing hematopoietic cells and disrupts stroma within the hematopoietic tissue. Both hematopoieti…
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status Open
Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short, which call for rational d…
View article: Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies
Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies Open
Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN …
View article: Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research
Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research Open
Slower progression of the disease in BALB/CaNn mice, greater possibility to examine the retina due to mild vitreous involvement, and later occurrence of exophthalmos makes this strain more suitable for further investigational research.
Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization Open
Mantle cell lymphoma (MCL) is a chronically relapsing B cell lymphoproliferative malignancy characterized by translocation t(11;14)(q13;q32), cyclin D1 overexpression and significant chromosomal instability. One of the main hypotheses of M…
Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients Open
Background Short interval from diagnosis (i.e., biopsy) to treatment initiation (DTI) is associated with aggressive behavior of lymphomas including diffuse large B-cell lymphoma (DLBCL), and it should be considered as an inclusion criteriu…
View article: Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy Open
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the fa…
Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-<i>b</i>]pyridazine Derivatives Identified by Scaffold Hopping Open
FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In this study, we investigated the suitabilit…
View article: Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma Open
Background Despite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-ta…
Cell-specific modulation of mitochondrial respiration and metabolism by the pro-apoptotic Bcl-2 family members Bax and Bak Open
Proteins from the Bcl-2 family play an essential role in regulation of apoptosis. However, they also possess cell death-unrelated activities that are less well understood. This prompted us to study apoptosis-unrelated activities of the Bax…
MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 Inhibitors in ibrutinib resistance mantle cell lymphoma Open
Background: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma. Bruton's tyrosine kinase (BTK) is a key component of B-cell receptor (BCR) signalling, implicated in B-cell cancers and an effective therapeutic tar…
View article: TYPE OF ATM ABERRATION HAS A DIFFERENT IMPACT ON SURVIVAL PARAMETERS IN MANTLE CELL LYMPHOMA
TYPE OF ATM ABERRATION HAS A DIFFERENT IMPACT ON SURVIVAL PARAMETERS IN MANTLE CELL LYMPHOMA Open
Introduction: The ataxia–telangiectasia mutated (ATM) gene plays an important role in the cellular response to DNA damage. Whether different types of ATM aberrations (mutation and/or deletion of (del)11q) differentially affect survival in …